Staurosporine

目录号:S1421 别名: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 2186.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。
靶点
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外研究

Staurosporine 也强抑制HeLa S3细胞,IC50为4 nM。[1]Staurosporine 也抑制多种其他蛋白激酶,包括PKA, PKG, 磷酸激酶, S6 激酶, 肌球蛋白轻链激酶(MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, 和Syk , IC50分别为 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, 和 16 nM。[3] Staurosporine (1 μM) 诱导 PC12细胞90%以上凋亡,这种作用可被过量表达的Bcl-2抑制,或者zVAD-fmk, cycloheximide (10 μM) 及actinomycin D (5 μM)处理也可抑制。相应地, Staurosporine处理,诱导细胞内游离钙水平 [Ca2+]i快速且持久的提升,线粒体活性氧(ROS)的积累,及 随后的线粒体功能障碍。[4]通过caspase-8激活和Bid 分裂,功能性caspase-3的表达可增强Staurosporine诱导MCF7细胞死亡。[5] 1 μM Staurosporine处理,只部分抑制IL-3刺激的Bcl2 磷酸化,而完全阻断PKC调节的 Bcl2磷酸化。[6] Staurosporine 诱导人类包皮成纤维细胞AG-1518凋亡,根据溶酶体组织蛋白酶D调节的 细胞色素 c释放和 caspase 激活。[7] 除了激活传统线粒体凋亡通路, Staurosporine触发一种新型内在凋亡通路, 依赖Apaf-1存在时对caspase-9的激活。[8]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells NHrHRXZEgXSxdH;4bYPDqGG|c3H5 NIXZRZo1QCCq M17CSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20[U0xPiEQvF2u NIrRNYUzOTN6OEG5NS=>
human colon cancer cell line (LoVo cells) MU\Qdo9tcW[ncnH0bY9vKGG|c3H5 M1SxR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iY3;sc44h[2GwY3XyJINmdGxibHnu[UApVG:YbzDj[YxteylidYPpcochVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88UU4> NYT1dIJ6OTF3OUG1NFU>
human LoVo cells M4\BTnBzd2yrZnXyZZRqd25iYYPzZZk> NILm[HU1QCC2bzC3NkBp NHLEUG1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzvWo8h[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigQ>? NH2ydpMzOjF6MkmyPS=>
P19 cells M4PTRWZ2dmO2aX;uJIF{e2G7 M{O2RmlvcGmkaYTpc44hd2ZiUHzheIVt\XRvZHXybZZm\CCpcn;3eIgh\mGldH;yJJJm[2WydH;yJIlvKFBzOTDj[YxteyxiSVO1NF0xNjByMjFOwG0v Ml;vNVU4PzF2MUm=
human BJ cells NWS0RodrS3m2b4TvfIlkyqCjc4PhfS=> NYfTWXY1PzJiaB?= NUXyZYg1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MD6wNFIh|ryPLh?= MYCyNlkzOTB6MR?=
human HT-29 cells MYDGeY5kfGmxbjDhd5NigQ>? MXSyJIg> NVqxNWlrTW[oZXP0JI9vKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFIhcHK|IIXzbY5oKEqFLUGgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHHzd4F6 NWHLZYJ4OjF2MkizO|U>
human A549 cells MXzDfZRwfG:6aXRCpIF{e2G7 MWW3NkBp M3nZOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgcYV1cG:m NHLnR5QyQDR6NEe3OS=>
human HT-29 cells NYXpW4JYTnWwY4Tpc44h[XO|YYm= Mmn0TY5pcWKrdHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBqdiCqdX3hckBJXC1{OTDj[YxteyC3c3nu[{BLSzFiZInlJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDwcIF1\SC{ZXHk[ZIh[XO|YYmsJGlEPTB;Mj61JI5O MYWyNVUyOzJ7Mx?=
human HT-29 cells MkHISpVv[3Srb36gZZN{[Xl? NEmzdFMzKGh? NEe2fo1KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJJJm\HWldHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBi\nSncjCyJIhzeyCkeTD1d4lv\yCMQ{Ggd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHPlcIwu[mG|ZXSgZZN{[XluIFXDOVA:Oi54IH7NMi=> MmnYNlE6PzNzMEG=
Sf9 cells M13GRWZ2dmO2aX;uJIF{e2G7 NUP1XIw6UW6qaXLpeIlwdiCxZjDoeY1idiCVeXug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0{KG6PLh?= NWnYdIZDOTh6MkO3PFQ>
human HUVEC MYXQdo9tcW[ncnH0bY9vKGG|c3H5 MWO0PEB1dyB5MjDo MnLFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVW\FR{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7 Mn\aNlIyQDJ7Mkm=
P19 cells MnHFSpVv[3Srb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKFC{b4TlbY4hU2mwYYPlJGEhcW5iUEG5JINmdGy|LDDJR|UxRTRibl2u NF7Zc4IyPTd5MUSxPS=>
Sf9 cells MX3GeY5kfGmxbjDhd5NigQ>? M336XWlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBucW5iYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSS M161WVE4OzF3OEWz
Sf21 cells M{jme2Z2dmO2aX;uJIF{e2G7 NEPlWZlKdmirYnn0bY9vKG:oIFrBT|Mh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOsJGlEPTB;NjDuUU4> M3TzNlE4ODh6MEW5
human colon carcinoma cell line HCT116 NGm0emZHfW6ldHnvckBie3OjeR?= NUn3NHA{S2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> NW\ONpV2OTV3M{ezOFU>
human ST486 cells M37WN3Bzd2yrZnXyZZRqd25iYYPzZZk> NE\OZZQ1QCC2bzC3NkBp MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOWNEi2JINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{BvVS5? MUWyNlE5Ojl{OR?=
human MDA-MB-231 cells MVrDfZRwfG:6aXRCpIF{e2G7 MlvvO|IhcA>? Ml\nR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9O{4yKG6PLh?= NELiV3UyQDR6NEe3OS=>
P19 cells MXLGeY5kfGmxbjDhd5NigQ>? NF;n[YFKdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v Ml\zNVU4PzF2MUm=
human DLD1 cells NIG4WJNRem:uaX\ldoF1cW:wIHHzd4F6 NHPwbIc1QC15MjDo MkTYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? M1zyUlIzOTh{OUK5
insect cells M4PlO2Z2dmO2aX;uJIF{e2G7 NUnnNW5yUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQbY0yKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMh[nliSGTSSkwhUUN3ME2xNEBvVS5? NXG2e5piOTlzN{mwO|Y>
V79 MZ cells MmjuSpVv[3Srb36gZZN{[Xl? M3rofWlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> MYmyOFQzOjVzOR?=
P19 cells NGfOR|ZHfW6ldHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> MV:xOVc4OTRzOR?=
Sf9 cells MXPGeY5kfGmxbjDhd5NigQ>? NHT6OIYzOCCvaX7z NFPvT4ZKdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFIxKG2rboOgZpkhTUyLU1GgbY4heHKnc3XuZ4Uhd2ZiMTD1cY9tN0xiQWTQMEBKSzVyPUG1JI5ONg>? NGXVXWoyPzNzNUi1Ny=>
human PBMC MVPGeY5kfGmxbjDhd5NigQ>? MUmyOEBp MYXTeZBxemW|c3nvckBw\iCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBRSk2FIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3ME2xOkBvVS5? M1jnXFE5PTh3MES2
human A549 cells MlXTR5l1d3SxeHnjxsBie3OjeR?= MWW0PEBp M4i4OWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9NlAhdk1w NEjzdlkzPTh{NUmzOC=>
human CEM cells MmjmR5l1d3SxeHnjxsBie3OjeR?= M3jVSlczKGh? MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OjNibl2u MmX5NlI6OjFyOEG=
human HeLa cells NWLpToJpS3m2b4TvfIlkyqCjc4PhfS=> MlK0OFghcA>? MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkWgcm0v M2nyfVI2QDJ3OUO0
human PC3 cells M3ywWGN6fG:2b4jpZ:Kh[XO|YYm= NHPuNVg1QCCq M3TLWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5JEwhUUN3ME2zNUBvVS5? NVftc3RWOjV6MkW5N|Q>
human SF268 cells M3nRR2N6fG:2b4jpZ:Kh[XO|YYm= NUTwcplSPDhiaB?= NE\wUJhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ4ODDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVQ1KG6PLh?= MXyyNVUyOzJ7NB?=
human MCF7 cells M3PCNWN6fG:2b4jpZ:Kh[XO|YYm= M13XXFQ5KGh? M3vOd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NEBvVS5? MXmyNVM5QDF7MR?=
HEK293 cells NFL1UGdEgXSxdH;4bYPDqGG|c3H5 MWS3NkBp NW[2UFRwS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v MUGyOFc3OzJ4Mh?=
HUE cells MmfhSpVv[3Srb36gZZN{[Xl? NEjI[mE6OCCvaX7z NW\qXmxVUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gTHVGKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWmVITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25idILlZZRm\CCob4KgPVAhdWmwczDi[YZwemViVlXHSkBkcGGubHXu[4Uh[nliRVzJV2EtKEmFNUC9O|Ahdk1w NVLqTWNsOjBzN{CxOlM>
human A431 cells MVnDfZRwfG:6aXRCpIF{e2G7 M3fyPFI1KCCq M2XiNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= MUiyNlU1OTB3MR?=
human Jurkat cells NV\zWG43WHKxbHnm[ZJifGmxbjDhd5NigQ>? NYPEeG1rSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBLSUt|IHX4dJJme3OrbnegTWwzNXO2aX31cIF1\WRiaIXtZY4hUnW{a3H0JINmdGy|LDDJR|UxRTdzIH7NMi=> M3u0ZVE6PDJ5MkCz
HEK293 cells Mn:2SpVv[3Srb36gZZN{[Xl? NGnkPJZKdmirYnn0bY9vKG:oIFnMMVghemWuZXHz[UBjgSCKRVuyPVMh[2WubIOg[ZhxemW|c3nu[{BRU0NvYnX0ZVItKEmFNUC9O|chdk1w MmP1NVU4PzF2MUm=
human KE-97 cells M2XNNmN6fG:2b4jpZ:Kh[XO|YYm= M{mwNVczKGh? MlrkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2UuQTdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOyEQvF2u MXiyOFMzQDJ6Mx?=
human CHOK1 cells MWjDfZRwfG:6aXRCpIF{e2G7 MlzJOFghcA>? NELlV|NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEUE:NMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5zMzFOwG0v MlT6NlE2OTN{OUS=
mouse NIH/3T3 cells M{TNWGN6fG:2b4jpZ:Kh[XO|YYm= M4myT|k3KGh? NX7Sd3pIS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v MlPHNlQ{PjF3MkG=
human A2780 cells NWTCc453S3m2b4TvfIlkyqCjc4PhfS=> NWr0cIN5QTZiaB?= M2\uUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= M1L2flI1OzZzNUKx
human 8505C cells NGHmUI1EgXSxdH;4bYPDqGG|c3H5 M1HpOVk3KGh? MnrQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NFnKcJMzPDN4MUWyNS=>
human 518A2 cells NXHCT4JqS3m2b4TvfIlkyqCjc4PhfS=> NWK5b49vQTZiaB?= NGjyXZFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5{IN88UU4> MlewNlQ{PjF3MkG=
human HuH7 cells NXPHVWJ1S3m2b4TvfIlkyqCjc4PhfS=> NXrZb2ttPzJiaB?= NHfzU4NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNizszNMi=> NX;wU2NWOjR|MkiyPFM>
FL5.12-Akt1 cells M4fRPXBzd2yrZnXyZZRqd25iYYPzZZk> MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\MOU4yOi2Da4SxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlI6KM7:TT6= MnzvNVY1ODN4Mk[=
human MiaPaCa-2 cells NYHhcpZtWHKxbHnm[ZJifGmxbjDhd5NigQ>? NX3CZ|RnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNbYFR[UOjLUKgZ4VtdHNuIFnDOVA:OC5|NzFOwG0v MlLCNVY1OTN5OEC=
human BGC823 cells NWDk[lR7S3m2b4TvfIlkyqCjc4PhfS=> NX3VWotNPzJiaB?= M2SxXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6IN88UU4> Mlu2NlQ{Ojh{OEO=
human MCF7 cells NHXjepREgXSxdH;4bYPDqGG|c3H5 Mn;nPVYhcA>? MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD60JO69VS5? NXHaenh2OjR|NkG1NlE>
human A549 cells NX3LSFNVS3m2b4TvfIlkyqCjc4PhfS=> NYqyd49GQTZiaB?= NWnKe5dSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u NUTJU25pOjR|NkG1NlE>
HEK293 cells MYHDfZRwfG:6aXRCpIF{e2G7 MnzVR5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|LDDFR|UxRTJizszNMi=> M2m4SVI2OzF4M{G3
human Raji cells  MW\DfZRwfG:6aXRCpIF{e2G7 NYnRXZY2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= MnT0NlU{OTZ|MUe=
human HepG2 cells MUfDfZRwfG:6aXRCpIF{e2G7 MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whTUN3ME2yJO69VS5? MoWwNlU{OTZ|MUe=
human BJ cells NFHlVo9EgXSxdH;4bYPDqGG|c3H5 NWXTflBwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMtKEWFNUC9NkDPxE1w MkLSNlU{OTZ|MUe=
human U937 cells MmnMR5l1d3SxeHnjxsBie3OjeR?= M3nPZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w NVjxR3luOTdyOEiwOlc>

... Click to View More Cell Line Experimental Data

体内研究 在局部贫血前,使用Staurosporine(0.1-10 ng)预处理局部贫血沙鼠和大鼠模型,可防止神经元损伤,这种作用存在剂量依赖性,说明CAl锥体细胞死亡涉及PKC。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
细胞实验:[4]
+ 展开
  • Cell lines: PC12
  • Concentrations: 溶于DMSO,终浓度为1 μM
  • Incubation Time: ~32 小时
  • Method: 使用Staurosporine处理细胞32小时。细胞在4%多聚甲醛中混合,然后使用DNA结合染料Hoechst 33342染色。在荧光照明下观察细胞,测定凋亡细胞百分数。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 短暂局部贫血的雄性Mongolian沙鼠或雄性 Wistar大鼠
  • Formulation: 溶于DMSO,然后在盐水中稀释
  • Dosages: ~10 ng
  • Administration: 定向处理到海马双边CA1子域
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 466.53
化学式

C28H26N4O3

CAS号 62996-74-1
稳定性 powder
in solvent
别名 CGP 41251

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00031681 Completed Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Estrogen Receptor-negative Breast Cancer|Extensive Stage Small Cell Lung Cancer|Gastrointestinal Stromal Tumor|HER2-negative Breast Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Ovarian Sarcoma|Ovarian Stromal Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Cell Lung Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Triple-negative Breast Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Unspecified Adult Solid Tumor Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary National Cancer Institute (NCI)|Washington University Siteman Cancer Center December 2001 Phase 1
NCT00012194 Terminated Unspecified Adult Solid Tumor Protocol Specific National Cancer Institute (NCI) March 2001 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PKC Signaling Pathway Map

相关PKC产品

Tags: 购买Staurosporine | Staurosporine供应商 | 采购Staurosporine | Staurosporine价格 | Staurosporine生产 | 订购Staurosporine | Staurosporine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID